CytoDyn : to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries

VANCOUVER - CytoDyn Inc. (OTC.QB: CYDY), ('CytoDyn' or the 'Company'), a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer, will host an investment community webcast on Wednesday, January 6, 2021.

Contact:

Michael Mulholland

Tel: [phone]

Email: [e-mail]

(C) 2021 Electronic News Publishing, source ENP Newswire